ELIAS Animal Health, a leading companion animal cancer therapeutics company, announced on Wednesday the appointment of Brian Segebrecht as chief revenue officer in anticipation of the impending product approval of the ELIAS Cancer Immunotherapy (ECI) in the fourth quarter of this year.
Segebrecht joins the ELIAS leadership team after leading Sentrx Animal Care as chief executive officer until last year. At the company based in Olathe, Kansas, he will lead the commercialization of the company’s first-in-class adoptive cell therapy, and drive new business partnerships for the expanding product pipeline at ELIAS.
“Brian’s track record of transforming commercial strategy and building value for shareholders make him the perfect fit as we move closer to the regulatory approval of ECI in Q4 of 2024,” said Chief Executive Officer Tammie Wahaus. “His leadership will be critical as we continue to pursue funding to support the commercialization of our lead product, as well as the continued expansion of our portfolio of companion animal cancer therapeutics.”
Segebrecht said, “I am both honoured and excited to join this amazing team in their important work in canine oncology. ECI is a disruptive innovation in the osteosarcoma space that will fill a real void in the current treatment options, and the ELIAS pipeline of innovations to follow ECI is equally special.”
Segebrecht’s appointment comes on the heels of a significant milestone for ELIAS Animal Health—based on pivotal study data, the United States Department of Agriculture Center for Veterinary Biologics determined early this year that ECI demonstrates a reasonable expectation of efficacy. The determination is a significant milestone in the licensing pathway. ECI is poised to be the only adoptive cell therapy of its kind approved for the treatment of canine osteosarcoma, a deadly form of bone cancer in dogs.
The company is pursuing a $10 million Series A capital raise to support manufacturing expansion and commercial launch of ECI. Funding will also support the continued development of the company’s product pipeline, which includes a novel oncolytic immunotherapy, a pilot study combining ECI with a conditionally approved checkpoint inhibitor, and a pilot study evaluating its adoptive cell therapy in large-breed dogs using a sophisticated surgical technique to avoid amputation.
Prior to commercial launch, which is expected later this year, ECI will continue to be available as an experimental biologic for veterinary use under ELIAS’s existing 9 CFR 103.3 authorization as the company finalizes the remaining regulatory actions to secure a first-in-class autologous prescription product licence.
Source: PR Newswire
Caution: Information in news reports, press releases, or articles on TheSnout.in is not intended to serve as a medical opinion or advice. Do not attempt to treat yourself or your pets without consulting the appropriate medical professional.
